Gravity Analytica

CytoSorbents to Report Third Quarter 2024 Operating and Financial Results

CTSO 10.17.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-07

Name of Upcoming Event:Live Conference Call

Full Press Release SEC Filings Our CTSO Tweets

About Gravity Analytica

Recent Filings

PRINCETON, N.J.,Oct. 17, 2024(GLOBE NEWSWIRE) --CytoSorbents Corporation(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2024 operating and financial results after the market close onThursday, November 7, 2024.

CytoSorbents’ management will host a live conference call, presentation webcast, and a question-and-answer session starting at4:30PM ETthe same day.

Webcast Details:Date:Thursday, November 7, 2024Time:4:30 PM ETLive webcast link:https://edge.media-server.com/mmc/p/e9gv3iawConference ID: 9258825

Participant Dial-In:Participant Dial-in toll-free: (800) 715-9871Passcode: 9258825

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.

An archived recording of the conference call will be available under the Investor Relations section of the Company’s website athttps://ir.cytosorbents.com/

AboutCytoSorbents Corporation(NASDAQ: CTSO)

CytoSorbents Corporationis a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents’ technologies are used in a number of broad applications. Two important ones are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents’ lead product,CytoSorb ^®, is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and forticagrelorandrivaroxabanremoval in cardiothoracic surgery procedures. CytoSorb has also receivedFDA Emergency Use Authorizationin the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States.

In theU.S.andCanada,CytoSorbentsis developing the DrugSorbTM-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received twoFDA Breakthrough Device Designations: one for the removal ofticagrelorand another for the removal of thedirect oral anticoagulants (DOAC) apixaban and rivaroxabanin a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. InSeptember 2024, the Company submitted a De Novo medical device application to theU.S.FDA requesting marketing approval to remove ticagrelor and reduce the severity of perioperative bleeding in CABG patients on the drug. The Company expects to submit its completed Health Canada Medical Device License (MDL) application, pending the expected receipt of Medical Device Single Audit Program (MDSAP) certification in the near future. DrugSorb-ATR is not yet approved or cleared inthe United StatesandCanada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY^®, CytoSorb-XLTM, HemoDefend-RBCTM, HemoDefend-BGATM, VetResQ^®, K⁺ontrolTM, DrugSorbTM, ContrastSorb, and others. For more information, please visit the Company’s website atwww.cytosorbents.comor follow us onFacebookandX.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with theSEConMarch 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

U.S.Company Contact:Peter J. Mariani, Chief Financial Officer305 College Road EastPrinceton, NJ08540pmariani@cytosorbents.com

Investor Relations Contact:Aman Patel, CFAICR-Westwickeir@cytosorbents.com

Source: CytoSorbents

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com